A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
Status:
Terminated
Trial end date:
2018-08-04
Target enrollment:
Participant gender:
Summary
The study is being performed to assess the MTD, pharmacokinetics (PK), safety, tolerability
and preliminary antitumor activity of DBPR112 in patients with head and neck cancer and EGFR
mutated lung cancer.